Preparedness for Clinical Trials in Medical Oncology Subspecialty Training in Canada - A National, Bi-Lingual Questionnaire

Abstract

Background: There is no standardized approach to clinical trial education for Canadian medical oncology subspecialty training. Canadian medical oncology subspecialty training programs have transitioned to a competency by design (CBD) educational framework. This study aims to determine whether current education practices in medical oncology subspecialty training programs in Canada prepare medical oncology trainees for participating in clinical trials as an investigator.

Methods: A national, online, bi-lingual questionnaire to understand exposure to clinical trials and general research in training, self-perceived competence, preparedness, and willingness to participate in clinical trials was conducted. Participants included medical oncology resident trainees and fellow trainees and new-to-practice physicians who have practiced in medical oncology for less than 5 years. All participants had to complete a medical oncology subspecialty training program in Canada. Data were collected from November 2021 to February 2022. Results are presented using descriptive statistics.

Results: Out of the 41 respondents (response rate: 15%), most were new physicians (41%), from Ontario (61%). 73% did not have formal training on how to participate in clinical trials as an investigator. 65% rated their competence in clinical trials as fair/poor and 74% rated their preparedness for clinical trials as fair/poor after training. 79% were willing to participate as an investigator in clinical trials after training. A correlation analysis revealed structured or in-clinic teaching in clinical trials trended towards improved self-evaluations of competence, preparedness, and willingness to participate in clinical trials (p > 0.05). Most respondents (56%) sought additional clinical trial education after training.

Conclusion: Training in clinical trials is highly variable. After training, most trainees do not feel competent or prepared to participate in clinical trials as an investigator, but they have a willingness to pursue clinical trials. Further assessment into how to produce competent medical oncology clinical trial investigators is warranted.